1 February 2026
Swissmedic: Changes to the Guidance Document Drug Safety Signals HMP and the Signal Notification Form
The Guidance document on Drug Safety Signals HMP has undergone a comprehensive revision, with its structure reorganised and its content clarified to improve clarity and readability. In addition, the Signal Notification Form has been updated to reflect the new requirements. Both the revised Guidance document and the updated Signal Notification Form came into effect on 1 February 2026.
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: Haemovigilance Annual Report 2025
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
European Medicines Agency: Highlights of the September 2026 Management Board meeting